Search

Search Constraints

You searched for: Author/Creator Adjei, Alex

Search Results

1. 2022-RA-464-ESGO A phase i dose escalation and expansion cohort trial of carboplatin and gemcitabine with the ATR inhibitor berzosertib in first or second recurrence platinum sensitive epithelial ovarian, peritoneal, and fallopian tube cancer. (20th October 2022)

2. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two. Issue 1 (November 2016)

3. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two. Issue 1 (November 2016)

4. 385 A first-in-human study of lemzoparlimab, a differentiated anti-CD47 antibody, in subjects with relapsed/refractory malignancy: initial monotherapy results. (10th December 2020)

5. 385 A first-in-human study of lemzoparlimab, a differentiated anti-CD47 antibody, in subjects with relapsed/refractory malignancy: initial monotherapy results. (9th November 2020)

6. A phase I study of the anaplastic lymphoma kinase inhibitor ceritinib in combination with gemcitabine‐based chemotherapy in patients with advanced solid tumors. Issue 12 (27th August 2021)

7. Consensus Report of the 2015 Weinman International Conference on Mesothelioma. Issue 8 (August 2016)

8. CTNI-23. PRELIMINARY SAFETY AND PHARMACOKINETICS DATA FOR A PHASE 1B TRIAL OF TELAGLENASTAT IN COMBINATION WITH RADIATION THERAPY AND TEMOZOLOMIDE IN PATIENTS WITH IDH-MUTANT GRADE 2/3 ASTROCYTOMA (NCI-10218). (14th November 2022)

9. Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1 antibodies. Issue 1 (23rd November 2018)

10. Weight loss over time and survival: a landmark analysis of 1000+ prospectively treated and monitored lung cancer patients. Issue 6 (17th September 2020)